In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Eli Lilly EL-468, a phenylenediamine, possesses the delayed-toxicity necessary for a bait toxicant to control colonies of the red imported fire ant, Solenopsis invicta Buren. In laboratory tests it ...

Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.

By Bhanvi Satija (Reuters) -The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted ...

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly ...

Eli Lilly and Co. on Thursday unveiled a $3 billion expansion of its facility in the Kenosha County. The announcement marked one of the biggest business developments in southeastern Wisconsin ...

Eli Lilly, the company that makes the blockbuster weight loss treatment Zepbound, will start studying its obesity products as treatments for alcohol and drug addiction, making it the first major ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.